Pabiththa Kamalraj

1. Introduction Sixty percent of patients with head and neck squamous cell carcinoma (HNSCC) present with locoregionally advanced disease that is treated with either surgery or radiation, often in combination with chemotherapy [1,2,3,4]. Unfortunately, there is a high rate of local, regional, or metastatic disease recurrence (20–30%) and only a minority of these patients are eligible for potentially curative salvage treatment [1,4,5,6].